ImmunoSite Technologies and MéCour have partnered to advance the automation of difficult and variable processes for cell handling by improving the quantity and quality of the PBMC yields and viability through automation.  The capability of freezing and thawing PBMC using the precisely controlled freezing rate in the MéCour system, coupled with an automated liquid handler,  facilitates the complete automation of  isolating cells, counting cells, loading the cells into cryovials, and freezing cells with automated precision. The enhanced throughput of cell isolation and handling processes allow larger and more diverse clinical studies.  DOWNLOAD the whitepaper now for all the details.

Call IST to discuss your automation needs at (888) 770-4478

Full release click here.

Fort Lauderdale, Fla. – October 18, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has helped to develop a Cell Culture Workshop that is offered  at the Employ Florida Banner Center for Life Sciences, based at Palm Beach State College’s Eissey Campus in Palm Beach Gardens.

Funded by Workforce Florida, Inc., the Banner Center for Life Sciences focuses on training and curriculum development in the life sciences industry and its biotechnology, pharmaceutical and medical device subsectors. It is unique in that the development of curricula is guided by an industry advisory council, and is based on current industry standards and needs for incumbent and future employees.

“The education of Florida’s workforce is vital for the growth of the life science industry in the state,” said Julie Wilkinson, Director of Pharma Services and Chief Information Officer of IST. “It’s been a great opportunity for IST to be associated with such a progressive program, and we look forward to continued interactions.”

IST is a logical partner to assist in the development of the curriculum for the Cell Culture workshop as the company specializes in the testing of clinical trial samples involved in biologics and other immune-based drug research, development and post-market surveillance. IST has decades of experience with biotechnology and diagnostics product development.

“Our program benefits greatly from industrial guidance and involvement,” said Libby Handel, Ph.D., director of the Banner Center for Life Sciences and director of Biotechnology Programs at Palm Beach State College. “IST’s insight is highly valued and will be paramount in the development of curriculum that will be used to educate, and ultimately strengthen Florida’s workforce.”

The Cell Culture Workshop offered on October 27 and 28 is enrolled fully; however, individuals interested in participating in this, or other workshops should contact the Banner Center for registration and fee information. For a schedule of upcoming workshops, please visit http://www.lifesciencesbannercenter.com/TrainingCalendar.

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/; follow IST on Twitter at http://twitter.com/ImmunoSite; or on Facebook at http://www.facebook.com/immunosite.For more information about the Employ Florida Banner Center for Life Sciences, pleasevisit http://www.lifesciencebannercenter.com.

About ImmunoSite Technologies

Formed in 2009 as a spin-off of Beckman Coulter, Inc., ImmunoSite Technologies, LLC (IST) offers a full range of contract research (CRO) for immune monitoring, particle testing, and process automation services for biotechnology, pharmaceutical, manufacturing and academic organizations around the world. Fully GLP compliant and based in Fort Lauderdale, Fla., IST’s team has 110 years of rigorous product development experience, has been published over 300 peer-reviewed scientific publications, has authored over 30 U.S. and international patents, and has developed and successfully commercialized over 200 diagnostic (IVD) product reagents, kits and instrument systems. IST is distinguished by its ongoing partnerships with best-in-class clinical trial organizations such as: the Immune Tolerance Network, the Immune Tolerance Institute, and the Imperial College of London-managed CD4 Initiative. This extensive immune monitoring and cell analysis R&D experience qualifies IST scientists to accelerate vaccine, biologic and drug discovery, and to comply with complex and demanding international scientific and governmental regulations.

About Employ Florida Banner Center for Life Sciences at Palm Beach State College

The Employ Florida Banner Center for Life Sciences at Palm Beach State College is Florida’s industry-driven resource for life sciences workforce education and training throughout the state.  Funded by Workforce Florida, Inc., this consortium of industry, workforce, and educational partners provides training and career advancement solutions for Florida’s life sciences industry, which includes medical devices, pharmaceutical and biotechnology.A resource for all educational institutions, economic development organizations, and regional workforce boards, the Banner Center provides leadership in the ongoing process of developing products and services to increase Florida’s competitiveness in the life sciences industry.

IST Press Contact:

Marketing Matters

Kyle E. Glass, Public Relations/Marketing Manager

Ph: 502-409-5953

Email: kyle@marketingmatters.net

Web: http://www.marketingmatters.net

Banner Center Contact:

Compass Marketing Communications
Carla Brown Lucas, President

Ph: 772-419-0444 (office)

Ph: 772-708-9626 (mobile)

Email:Carla@compassmarcom.com

Web:http://www.compassmarcom.com

Dextramers are superior reagents for the detection of antigen-specific T cells, having the ability to interact simultaneously with multiple receptors on a single T cell with unsurpassed avidity. The increased avidity of Dextramers compared to conventional MHC multimer reagents enhances resolution and signal-to-noise ratio providing a more accurate assessment of the T cell response, and clearly identifying responses previous generation technologies might miss.

In compliance with cGLP quality standards, IST specializes in incorporating antigen-specific responses in assay solutions to evaluate the safety and efficacy of vaccines and biologics.  IST offers expertise in confirming the validity of processes involved in such studies. Together with Immudex’s Dextramer™ technology, IST now offers enhanced capabilities to validate the effectiveness of potential vaccines and biologics, and thereby significantly improve the efficiency and cost-effectiveness of drug development and production.

Through the partnership, IST can refer clients that need to gauge T cell response to Immudex, and Immudex can refer clients that have other immune monitoring needs to IST. IST immune monitoring services include custom assay design, optimization, automation and validation; cell mediated immunity; functional immune monitoring and much more. This alliance adds to the capabilities of both companies while streamlining processes – providing for faster, more accurate results for customers. By accurately gauging the effect of an immunotherapy, researchers can reduce a study’s timeline by weeks or even months, and more importantly, can avoid wrong and costly decisions based on weak and inaccurate data. This can prove invaluable during all phases of clinical trials, driving significant cost savings and productivity.

“If you’ve ever been on a conference call with eight separate vendors trying to figure out if a pharmaceutical is working, then you’ll understand why this partnership is beneficial to our industry,” said Wade Bolton, Ph.D., President of IST. “Immudex offers a technology that is superior in gauging T cell responses and we’re honored to call them partners.”

“IST’s standardization, validation and automation of custom assays are the best in the industry,” said Stephen Haley, Ph.D., Vice President and Director of U.S. Operations for Immudex. “This partnership greatly increases our offering capabilities and is poised to be a great asset to our current and future clients.”

The alliance is not an exclusive partnership. IST still has the ability to use other technologies when deemed more appropriate or to meet a client’s request.

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/; follow IST on Twitter at http://twitter.com/ImmunoSite; or follow on Facebook at http://www.facebook.com/pages/ImmunoSite-Technologies-LLC/167604859950599. For more information on Immudex, visit http://www.immudex.com/.

About ImmunoSite Technologies

Based in Ft. Lauderdale, FL, ImmunoSite Technologies, LLC (IST) offers a full range of contract research (CRO) immune monitoring services to leading biotechnology, pharmaceutical, and academic organizations around the world to provide products and services that span all stages of drug discovery and development. IST is rapidly building a worldwide reputation for services related to qualifying, standardizing, and when appropriate, automating assays associated with cell-mediated immunity. By using qualified reagents, controls, standards and processes, IST-developed functional assays perform within tight specifications and yield reproducible results, helping pharmaceutical and biotechnology companies to accelerate drug discovery, document clinical relevance and reduce costs. The IST team has been distinguished by their ongoing partnerships with best-in-class clinical trial organizations such as: the Immune Tolerance Network, the Immune Tolerance Institute, and the Imperial College of London-managed CD4 Initiative. This extensive cell analysis R&D experience qualifies IST scientists to comply with complex and demanding international scientific and governmental regulations.

About Immudex

Based in Copenhagen, Denmark with North American operations based in Fairfax, Virginia, Immudex is the sole proprietor of the MHC Dextramer technology. Immudex develops and commercializes products for the quantitation, characterization, and generation of antigen-specific T-cell responses for life science research, in vitro diagnostics and vaccine development. Immudex has a number of Research Use Only (RUO) products on the market, two products under development for in vitro diagnostic use, as well as a vaccine candidate in development for one of the most deadly of human diseases.

Press Contact:

Marketing Matters

Kyle E. Glass, Public Relations/Marketing Manager

Ph: 502-409-5953

Email: kyle@marketingmatters.net

Web: http://www.marketingmatters.net

Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a recent collaboration agreement.

As part of the agreement, ImmunoSite Technologies (IST) will utilize its extensive industry expertise and experience to perform particle testing for Beckman Coulter customers using Beckman Coulter’s particle testing instrumentation. IST will employ technologies from the “Coulter Principle”, laser diffraction, dynamic light scattering, zeta potential and BET analysis to test all aspects of particulate samples.

IST employs a wide range of technologies to solve all kinds of particle analysis challenges for clients from general chemical and manufacturing to pharmaceutical and cosmetics.

IST and Beckman Coulter particle testing customers benefit from ImmunoSite Technologies’ quick sample-analysis turnaround and superior customer service—including strict confidentially of all data and samples. With 21 CFR part 11 systems available, all samples handled by IST are analyzed with superior methodologies and with the benefit of the latest particle testing technologies and systems. Additionally, all analysis procedures and results data undergo extensive reviews, ensuring that customers receive the best results possible.

ImmunoSite Technologies’ outstanding Good Laboratory Practices (GLP) status was also one of the factors in being selected as a Beckman Coulter partner. IST conducts particle testing for leading companies throughout a wide-range of industries; ranging from pharmaceuticals to various construction materials, cosmetics and more. All protocols for sample handling and data reporting exceed the current GLP standards, reinforcing IST’s commitment to addressing its customer’s requirements for quality control, regulatory compliance and auditing.

“We are extremely confident in the abilities of particle testing and the services we provide to help us solve our customers’ complex problems,” said Wade Bolton, Ph.D., CEO of IST. “This is an important adjunct to our current pharma services in immune monitoring and surveillance.”

For more information on ImmunoSite Technologies, please visit http://immunositetechnologies.com/; follow IST on Twitter at http://twitter.com/ImmunoSite; or follow on Facebook at http://www.facebook.com/pages/ImmunoSite-Technologies-LLC/167604859950599

About ImmunoSite Technologies

Based in Ft. Lauderdale, FL, ImmunoSite Technologies, LLC (IST) offers a full range of contract research (CRO) immune monitoring services to leading biotechnology, pharmaceutical, and academic organizations around the world to provide products and services that span all stages of drug discovery and development. The company is uniquely qualified to develop assays and conduct testing to assess immune status and function. IST is rapidly building a worldwide reputation for services related to qualifying, standardizing, and when appropriate, automating assays associated with cell-mediated immunity. IST services include flow cytometry, particle characterization, application development, automation, assay development and testing. By using qualified reagents, controls, standards and processes, IST-developed functional assays perform within tight specifications and yield reproducible results, helping pharmaceutical and biotechnology companies to accelerate drug discovery, document clinical relevance and reduce costs.

A privately held company, IST was formed in August, 2009, to bring together a highly qualified team of industry leading immune system research and development scientists who together have more than 100 years of experience developing and performing assays related to immune monitoring and surveillance. The IST team has been distinguished by their ongoing partnerships with best-in-class clinical trial organizations such as: the Immune Tolerance Network, the Immune Tolerance Institute, and the Imperial College of London managed CD4 Initiative. This extensive cell analysis R&D experience qualifies IST scientists to comply with complex and demanding international scientific and governmental regulations.

Press Contact: Marketing Matters
Scott Moody, Director of Public Relations
Ph: 954-925-1511
Email: scott@marketingmatters.net
Web: http://www.marketingmatters.net

Link to this release on PRWeb: http://www.prweb.com/releases/2011/04/prweb5219304.htm

What Do You Seek In A Contract Research Partnership?

In a time of tight budgets and careful examination of the cost/benefit of partnering with a contract research service provider, ImmunoSite Technologies, LLC (IST) offers a rare combination of experience, knowledge, responsiveness, and trustworthiness.  IST knows what clients need to be successful, and how to provide the highest quality in service.  Clients can depend on ImmunoSite Technologies to be the ideal partner that helps accelerate their success without encumbering their resources.

Cost efficiency – As R&D costs escalate, you need a CRO partner that fits well with your business from a cost/value point-of-view, as well as a shared values point-of-view.  IST understands this and is ready to work with you to craft a partnership that works for you from a time, resource, and cost perspective, all the while delivering the results you need.  IST demonstrates value in the services they provide, by getting the work done quickly and on budget without sacrificing quality.

Knowledge and experience – Backed by years in pharmaceutical, biotech, and diagnostics product development, IST knows the challenges of developing the right assay to get the accuracy, precision and reproducibility needed to succeed.

Compatibility and communication – Essential to a great partnership, is a high level of compatibility and great communications.  IST’s professionals understand this.  You need a team that understands your company and your goals, your particular research objectives and challenges.  You need professionals that will work with you to plan, implement and work through all challenges along the way.  The team at IST has partnered with organizations from around the globe so they know the value of accurate communications and a shared vision to bring creative solutions to fruition, while fostering long-term and productive relationships.

Quality – Outsourcing your assay automation project to a qualified partner like IST is a key strategy for ensuring quality.  In a business where service, precision, accuracy, and timeliness are the key deliverables, IST stands apart by putting the “service” back into the service provider partnership.  Quality is central to their work and the unique value they deliver.  The IST quality system is in compliance with GxP guidelines and international safety and regulatory requirements.

Specialization in assay automation – This is IST’s niche and they provide the unique service that validates the automated assay performance with the client’s samples before the system ever leaves the ImmunoSite Technologies facility.  This offers great peace of mind to their clients who are investing significantly in automation to enhance their productivity, but don’t have the time or people to dedicate to implementing a new automated assay project.  IST has designed and developed automated systems for handling biological specimens from live cells to protein to nucleic acids.  Automation doesn’t have to fill a room to meet your needs.  Engineers at IST are cognizant of space and budget requirements when designing the best system for a client so the solution can be a simple benchtop or hood-sized system.

Explore a Partnership With ImmunoSite Technologies

If great service from a dependable, trustworthy, and experienced partner is what you are seeking for your assay automation project, then contact IST now. The technical experts and management team at ImmunoSite Technologies will meet with you to explore the fit between your company, your project needs and IST capabilities.  When it is a great fit, everybody knows.  IST assay automation services